Something about "individualized dosing." And now you're here, doing exactly what a smart consumer should do - researching before you spend a dollar
Two weeks later, you do it again
Safety first, jokes second
However, important limitations exist in the current evidence: Most studies have been relatively small with short follow-up periods Many participants had concurrent obesity, making it difficult to separate weight loss effects from direct effects on binge eating behaviour Long-term efficacy and safety data specifically for binge eating disorder are lacking The psychological and behavioural components of BED may require interventions beyond pharmacological appetite suppression There is no official link established by regulatory bodies between GLP-1 agonists and binge eating disorder treatment
Additionally, severe, persistent abdominal pain could indicate pancreatitis or gallbladder disease (both recognised risks with GLP-1 receptor agonists) rather than diverticulitis
Check in for refills and dose changes as needed